COLEC12: A Promising Drug Target and Biomarker for Nurse Cell Scavenger Receptor 2

Target Name: COLEC12

NCBI ID: G81035

COLEC12

COLEC12: A Promising Drug Target and Biomarker for Nurse Cell Scavenger Receptor 2

Nurse cell scavenger receptor 2 (COLEC12) is a G protein-coupled receptor (GPCR) that plays a crucial role in various physiological processes in the body. Its primary function is to detect the presence of exogenous substances, such as toxins, drugs, and other harmful substances, in the environment and to initiate an immune response to eliminate them. COLEC12 is expressed in various tissues and cells throughout the body, including the nervous system, endocrine system, and immune system. Therefore, it is a potential drug target and biomarker for various diseases.

Diseases and COLEC12

COLEC12 is involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its role in cancer progression is well documented, as it has been shown to be involved in the development and progression of various types of cancer. For example, studies have shown that COLEC12 is expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, COLEC12 has been shown to play a role in the regulation of cancer cell survival and angiogenesis.

In neurodegenerative diseases, COLEC12 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that COLEC12 is involved in the regulation of neurotransmitter signaling, and that its dysfunction may contribute to the progression of neurodegenerative diseases.

In autoimmune diseases, COLEC12 has been shown to be involved in the development and regulation of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. Studies have shown that COLEC12 is involved in the regulation of immune cell function and that its dysfunction may contribute to the development and progression of autoimmune diseases.

COLEC12 as a Drug Target

COLEC12 has been identified as a potential drug target due to its involvement in various diseases. Because of its involvement in cancer, neurodegenerative diseases, and autoimmune diseases, COLEC12 has potential as a therapeutic target for these diseases.

One approach to targeting COLEC12 is to block its function as a receptor. Small molecules have been shown to be effective in blocking COLEC12, including inhibitors of GPCR signaling, such as aldosterone antagonists and muscarinic antagonists. Additionally, antibody-conjugated nanoparticles have been shown to be effective in delivering small molecules to COLEC12-expressing cells and blocking their function.

Another approach to targeting COLEC12 is to modulate its expression. Genetic modifiers, such as RNA interference and CRISPR/Cas9, have been shown to be effective in modulating COLEC12 expression and its function.

COLEC12 as a Biomarker

COLEC12 has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be involved in the regulation of various physiological processes, including inflammation, neurotransmission, and cancer progression. Therefore, its levels can be used as a biomarker for various diseases.

COLEC12 has been shown to be involved in the regulation of inflammation. Studies have shown that COLEC12 is involved in the regulation of inflammatory responses and that its dysfunction may contribute to the development of inflammatory diseases, including rheumatoid arthritis and multiple sclerosis.

COLEC12 has also been shown to be involved in the regulation of neurotransmission. Studies have shown that COLEC12 is involved in the regulation of neurotransmitter signaling and that its dysfunction

Protein Name: Collectin Subfamily Member 12

Functions: Scavenger receptor that displays several functions associated with host defense. Promotes binding and phagocytosis of Gram-positive, Gram-negative bacteria and yeast. Mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. Binds to several carbohydrates including Gal-type ligands, D-galactose, L- and D-fucose, GalNAc, T and Tn antigens in a calcium-dependent manner and internalizes specifically GalNAc in nurse-like cells. Binds also to sialyl Lewis X or a trisaccharide and asialo-orosomucoid (ASOR). May also play a role in the clearance of amyloid-beta in Alzheimer disease

The "COLEC12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COLEC12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets